ストックスクリーナーアプリを入手
2.4234
1.04%
0.0234
InspireMD Inc. (NSPR) 最新ニュース
InspireMD Inc. Breakout Confirmed by Volume MetricsJuly 2025 Momentum & Reliable Volume Spike Trade Alerts - newsimpact.co.kr
Is InspireMD Inc. stock undervalued right now2025 Key Lessons & AI Driven Price Forecasts - kangso.co.kr
Is InspireMD Inc. stock bottoming outJuly 2025 Drop Watch & Smart Allocation Stock Reports - Newser
Price action breakdown for InspireMD Inc.2025 Market Trends & Long-Term Growth Stock Strategies - Newser
Can a trend reversal in InspireMD Inc. lead to recoveryWeekly Market Report & Growth Focused Stock Pick Reports - Newser
Using data tools to time your InspireMD Inc. exitJuly 2025 Trends & Stock Portfolio Risk Management - Newser
InspireMD Inc. stock trend forecastJuly 2025 Momentum & Weekly Market Pulse Alerts - Newser
Will InspireMD Inc. stock recover after recent drop2025 EndofYear Setup & AI Enhanced Execution Alerts - Newser
Is InspireMD Inc. still worth holding after the dipJuly 2025 Price Swings & Expert Verified Movement Alerts - Newser
Is InspireMD Inc. forming a bottoming baseQuarterly Market Review & AI Enhanced Execution Alerts - Newser
Is a relief rally coming for InspireMD Inc. holders2025 Breakouts & Breakdowns & Real-Time Volume Triggers - Newser
Rosalind Advisors Expands Stake in InspireMD Inc. with Strategic Acquisition - AInvest
Will InspireMD Inc. Hold Gains Into CloseJuly 2025 Technicals & Low Volatility Stock Suggestions - sundaytimes.kr
Quant Models Detect Momentum Reversal in InspireMD Inc.July 2025 Sentiment & Safe Capital Growth Stock Tips - newsyoung.net
Global Embolic Protection Devices Market Set to Experience Unprecedented Growth at a CAGR of ~8% by 2032 | DelveInsight - GlobeNewswire Inc.
What earnings revisions data tells us about InspireMD Inc.Quarterly Profit Summary & Consistent Growth Stock Picks - Newser
Why InspireMD Inc. stock attracts strong analyst attentionFree Low Volatility Stable Growth Picks - Newser
What MACD signals say about InspireMD Inc.Summary of Trade Cycles in 5-Year Range - Newser
Bollinger Bands Show Potential Breakout in InspireMD Inc.Profit Focused Stock Screener Results Released - beatles.ru
Is InspireMD Inc. showing insider buyingExtreme Return Watchlist - sisaissue.com
InspireMD signals robust U.S. CGuard Prime launch progress and expands clinical pipeline following $58M capital infusion - MSN
InspireMD, Inc. (NASDAQ:NSPR) Q2 2025 Earnings Call Transcript - Insider Monkey
InspireMD Q2 Earnings: Revenue Down, CEO Confident in Future Growth - AInvest
InspireMD Reports Q2 2025 Financial Results and Milestones Amid FDA Approval and US Launch of CGuard Prime Carotid Stent System - AInvest
InsureMD Navigates Trade Policy Risks with US Manufacturing Plans - AInvest
InspireMD Inc (NSPR) Q2 2025 Earnings Call Highlights: Strategic US Launch Amid Financial Challenges - Investing.com Canada
InspireMD Inc. Navigates Trade Policy Risks with U.S. Manufacturing Plans - TipRanks
InspireMD Inc. Reports Q2 2025 Earnings and Regulatory Milestones - TipRanks
InspireMD’s Earnings Call: FDA Approval and Financial Challenges - TipRanks
InspireMD reports Q2 EPS (26c) vs (22c) last year - TipRanks
InspireMD's Strategic U.S. Expansion and Product Launch Momentum: A Balancing Act of Optimism and Caution - AInvest
InspireMD's Strategic Capital Raise and Clinical Innovation Position It as a High-Conviction Growth Play in the $5B+ U.S. Coronary Stent Market - AInvest
InspireMD's Q2 2025: Key Contradictions in FDA Approval, Product Launches, and U.S. Market Strategy - AInvest
InspireMD Experiences Robust US Launch Progress and Expands Clinical Pipeline Following $58M Investment - AInvest
InspireMD shares fall 1.50% intraday despite Q2 revenue beating estimates. - AInvest
Earnings call transcript: InspireMD Q2 2025 misses EPS forecast, stock rises - Investing.com Canada
Earnings call transcript: InspireMD Q2 2025 misses EPS forecast, stock rises By Investing.com - Investing.com South Africa
InspireMD earnings missed by $0.05, revenue fell short of estimates - Investing.com Canada
InspireMD Reports Q2 2025 Financial Results and Milestones - TipRanks
InspireMD's Q2 Results: Revenue Misses Expectations, GAAP EPS at -$0.26 - AInvest
InspireMD Announces Second Quarter 2025 Financial Results and Investor Conference Call Details - Quiver Quantitative
InspireMD gets FDA approval for CGuard Prime carotid stent system. - AInvest
InspireMD Reports Second Quarter 2025 Financial Results - GlobeNewswire
InspireMD Secures FDA Approval for Revolutionary Stroke Prevention Stent, Raises $58M for US Launch - Stock Titan
InspireMD Inc. Outperforms Peers on Volume MetricsTrade Ready Stock Watch for Short Term Published - metal.it
InspireMD, Inc. SEC 10-Q Report - TradingView
InspireMD's Q2 2025 Earnings and Strategic Momentum: A Path to Profitability Amid Uncertainty - AInvest
Does InspireMD Inc. stock perform well during market downturnsUnlock daily stock market insights for success - Jammu Links News
What makes InspireMD Inc. stock price move sharplyInvest confidently with daily market forecasts - Jammu Links News
What analysts say about InspireMD Inc. stockHigh-impact stock picks - Jammu Links News
What is the dividend policy of InspireMD Inc. stockUnlock powerful market analysis and alerts - Jammu Links News
How volatile is InspireMD Inc. stock compared to the marketSuperior profit margins - Jammu Links News
What is InspireMD Inc. company’s growth strategyOutstanding yields - Jammu Links News
Is it the right time to buy InspireMD Inc. stockMaximize returns with strategic trading plans - Jammu Links News
How strong is InspireMD Inc. company’s balance sheetFree Predictions - Jammu Links News
InspireMD's Turnaround: Sustainable Progress or Fleeting Optimism? - AInvest
Investors in InspireMD (NASDAQ:NSPR) from five years ago are still down 60%, even after 11% gain this past week - Yahoo Finance
Strategies to average down on InspireMD Inc.Real Chart Based Opportunity Identification - Newser
When is InspireMD Inc. stock expected to show significant growthAccess high-quality stock research instantly - Jammu Links News
0.37%
0.52%
大文字化:
|
ボリューム (24 時間):